Today: 27 February 2026
Subscribe
Browse Category

LSE:GSK 26 December 2025 - 26 January 2026

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
24 January 2026
·····
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···
GSK share price slips into the weekend as investors brace for Feb. 4 results

GSK share price slips into the weekend as investors brace for Feb. 4 results

GSK shares fell 1.7% to 1,816.5 pence in London Friday, with trading volume above recent averages. Senior executives disclosed routine share purchases via dividend reinvestment. Investors now await GSK’s fourth-quarter results on Feb. 4 and the upcoming dividend timetable. Debate continues over U.S. fast-track drug approvals, with GSK linked to the FDA’s voucher program.
18 January 2026
··
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK shares fell 1.7% to 1,817 pence in London Friday, extending a three-day slide and closing 11.7% below their December peak. Trading volume surged to 12.6 million shares. Filings showed senior executives reinvested dividends into shares and U.S. ADSs. Investors are awaiting GSK’s full-year results and U.S. drug-approval updates in early February.
17 January 2026
·····
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
14 January 2026
···
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK said its hepatitis B drug bepirovirsen met primary endpoints in two phase III trials, with global filings planned from early 2026. Shares closed up 4.3% after the news. The European Commission approved a new syringe format for Shingrix, and Japan cleared Exdensur for severe asthma. Investors await full phase III data on bepirovirsen’s durability and safety before sales impact is clear.
7 January 2026
··
London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

The FTSE 100 closed at 9,870.68 in a muted, low-volume session ahead of the Christmas break, down about 0.2%. Despite the quiet finish, the index is up 20.7% for 2025, on track for a fifth consecutive yearly gain. U.S. markets ended Friday nearly flat, while gold and silver hit new records. London trading resumes Monday amid thin liquidity and strong commodity moves.
28 December 2025
···
London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

The London Stock Exchange remains closed for the weekend and will reopen at 8:00 a.m. London time on Monday, December 29. The FTSE 100 ended the Christmas Eve half-day at 9,870.68, down 0.2%. The index is on track for a 20.7% annual gain, outperforming the S&P 500. The Bank of England cut its policy rate to 3.75% in December.
27 December 2025
···
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK’s U.S. ADR closed at $48.96 after the FDA approved its twice-yearly asthma drug Exdensur, but withheld approval for a related use. The company also reached a U.S. drug-pricing deal affecting its respiratory products and reported progress on vaccine expansion in Europe. London trading paused for holidays. Shingrix faces new competition.
26 December 2025
···
UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

The London Stock Exchange is closed Friday for Boxing Day, halting UK trading after a shortened Christmas Eve session where the FTSE 100 slipped 0.2%. Investors are watching global moves and a spike in precious metals, which could impact London-listed miners when trading resumes. BP agreed to sell a 65% stake in Castrol to Stonepeak for about $6 billion. The FTSE 100 is on track for a roughly 21% gain in 2025.
26 December 2025
·····
1 2 3 4
Go toTop